Evidence map›Paper›PMID 42255197›Full record

ArticleNational science review2026

Uncoupling tumor immunogenicity from cell death with platinum(IV)-antibody conjugates.

Liu-Yi Liu, Wenhao Yu, Yilong Liu, Yang Yang, Qiuyang Wei, Zihan Zhao, Rong Yang, Jie P Li, Zijian Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in National science review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liu-Yi LiuState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Wenhao YuState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Yilong LiuState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Yang YangState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Qiuyang WeiState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Zihan ZhaoDepartment of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Rong YangDepartment of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Jie P LiState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Zijian GuoState Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platinum drugs remain mainstays for solid tumors, but systemic toxicity and difficult dose finding in immunotherapy combinations limit their use. We engineer platinum(IV)-antibody conjugates [Pt-ADCs (platinum-based antibody-drug conjugates)] that confine a 'metal immune effect' to tumors while reducing off-tumor exposure. Site-specific glycoengineering installs redox-responsive Pt(IV) prodrugs at defined drug-to-antibody ratios, yielding homogeneous conjugates. Mechanistic profiling shows that cisplatin-derived, but not oxaliplatin-derived, payloads undergo efficient reductive activation in the tumor milieu; cinnamate-capped variants optimize serum stability, intratumoral release, and immunostimulatory signaling. In syngeneic models, Pt-ADCs deliver a low dose of cinnamate-capped Pt to upregulate major histocompatibility complex class I on tumor cells, expand tumor-reactive T-cell receptor clonotypes, and synergize with PD-1 blockade to suppress tumor growth, with minimal systemic toxicity. These findings position Pt-ADCs as a detoxified, immunogenic modality that uncouples immunogenic priming from high-dose cytotoxicity and offers a tractable path to rational dosing in chemo-immunotherapy combinations.

Indexed as

chemo-immunotherapy combinationsplatinum(IV)–antibody conjugatestumor immunogenicityupregulation of MHC-I

Identifiers

PMID42255197
PMCPMC13234940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.